

abbvie

# CREDIT SUISSE HEALTHCARE CONFERENCE

Bill Chase, Executive Vice President, Finance and CFO

November 13, 2014



# Disclaimer and Forward-Looking Statement

---

This presentation and its contents are confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose.

This presentation is neither an offer to purchase nor a solicitation of an offer to sell securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful.

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements.

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” in AbbVie’s 2013 Annual Report on Form 10-K and in Item 1A, “Risk Factors” of Part II of AbbVie’s second quarter 2014 Quarterly Report on Form 10-Q, which have been filed with the Securities and Exchange Commission.

AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

## 2014: Accomplishments to Date

---

Strategy Focused on **Delivering Strong Results and Returns for Shareholders**,  
Ensuring AbbVie is a **Sustainable Growth Business**

1

Delivering strong operational performance and shareholder returns

2

Significantly raised 2014 earnings outlook

3

Driving double-digit growth from HUMIRA and several other products

4

Delivering margin improvement and continued investment

5

Advancing our compelling pipeline

Continued progress toward building a  
platform for **future growth and innovation**

# Key Products with Category Leadership Positions

---

**HUMIRA**  
adalimumab

Unique attributes  
differentiate from  
competitive agents

**CREON**<sup>®</sup>  
(pancrelipase)  
Delayed-Release Capsules

Leading pancreatic enzyme  
replacement therapy

**Lupron Depot**<sup>®</sup>  
(leuprolide acetate for depot suspension)

Leading hormone therapy  
for the palliative treatment  
of advanced prostate cancer

**SYNAGIS**<sup>®</sup>  
PALIVIZUMAB

Only approved product for  
prevention of RSV

**Synthroid**<sup>®</sup>  
(levothyroxine sodium tablets, USP)

Leading branded  
synthetic hormone for  
thyroid disease

 **Duodopa**

Novel therapy for advanced  
Parkinson's disease

## Strongest Late-Stage Pipeline in Our History

---

40 active clinical development programs underway

Programs in large and growing specialty categories

12 programs in Phase 3 development or under regulatory review

Robust pipeline of mid-stage assets

Potential sales projections  
from late-stage pipeline represent **significant opportunity**

# Late Stage Pipeline Highlights: HCV Interferon-Free Combination

- Upon approval, AbbVie’s HCV therapy poised to be a breakthrough offering for patients
- Regulatory review progressing well
  - Actively engaged with regulators
  - Fully prepared for launch
- Significant body of data supports strong therapeutic profile across GT1 populations
- Global footprint, strong commercial execution capabilities
- Well positioned for success in large and growing market
- Second-generation program also progressing well, currently in Phase IIB development

Phase III Data	
ABBV Regimen + RBV	SVR 12 Rates
<b>SAPPHIRE-I</b> (GT1 naïve)	96%
<b>SAPPHIRE-II</b> (GT1 exp.)	96%
ABBV Regimen +/- RBV	SVR 12 Rates
<b>PEARL-II</b> (GT1b exp.)	97% w/RBV 100% RBV-free
<b>PEARL-III</b> (GT1b naïve)	99% w/RBV 99% RBV-free
<b>PEARL-IV</b> (GT1a naïve)	97% w/RBV 90% RBV-free
Special Populations	SVR 12 Rates
<b>TURQUOISE-II</b> (GT1 cirrhotics)	92% 12 weeks 96% 24 weeks

## Late-Stage Pipeline Highlights: Oncology

Compound	Mechanism	Indication
<b>ABT-199</b>	<b>Bcl-2 inhibitor</b>	Chronic Lymphocytic Leukemia (Phase III) Acute Myelogenous Leukemia and Other Hematologic Malignancies (Phase II)
<b>Duvelisib</b>	<b>Dual PI3K inhibitor</b>	Chronic Lymphocytic Leukemia (Phase III) Indolent Non-Hodgkin Lymphoma (Phase II)
<b>Veliparib</b>	<b>PARP inhibitor</b>	Neoadjuvant treatment of TNBC (Phase III) Squamous NSCLC (Phase III) BRCA Breast (Phase III) Non-squamous NSCLC (Phase III) Brain Metastasis and Other Cancers (Phase II)
<b>ABT-414</b>	<b>Anti-EGFR</b>	Glioblastoma Multiforme (Phase II)
<b>Elotuzumab</b>	<b>SLAMF7</b>	Multiple Myeloma (Phase III)

## Late Stage Pipeline Highlights: Other Promising Opportunities

Compound	Mechanism	Indication
<b>Daclizumab</b>	Humanized antibody specific for IL2 receptor	Relapsing Remitting Multiple Sclerosis (Phase III)
<b>Elagolix</b>	GnRH antagonist	Endometriosis (Phase III) Uterine Fibroids (Phase IIB)
<b>Atrasentan</b>	Selective endothelin-A receptor antagonist	Diabetic Kidney Disease (Phase III)
<b>GLPG0634</b>	Selective JAK-1 inhibitor	Rheumatoid Arthritis (Phase IIB) Crohn's Disease (Phase II)
<b>ABT-494</b>	Selective JAK-1 inhibitor	Rheumatoid Arthritis (Phase II)



# Returning Cash to Shareholders

---

Significant and growing cash flow

Recently increased quarterly dividend by nearly 17%

New \$5 billion share buyback program recently announced

**Strong commitment** to growing our dividend and returning cash to shareholders

## Established a strong foundation as an independent company

---

- Focused on executing on key strategic priorities
- Strong track record of exceeding financial commitments
- Generated significant shareholder returns
- Driving leading performance of HUMIRA and other key products
- Advancing promising pipeline to fuel future growth

---

**Strategic actions fortify AbbVie's position of strength, set up company for sustainable success for many years to come**

abbvie